Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Purchased by Bokf Na

BOKF NA increased its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 599,500.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 11,992 shares of the biotechnology company's stock after acquiring an additional 11,990 shares during the quarter. BOKF NA's holdings in Sarepta Therapeutics were worth $1,496,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the business. Charles Schwab Investment Management Inc. raised its stake in shares of Sarepta Therapeutics by 2.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 623,749 shares of the biotechnology company's stock worth $75,842,000 after acquiring an additional 12,000 shares during the last quarter. Proficio Capital Partners LLC acquired a new position in shares of Sarepta Therapeutics in the 4th quarter valued at $3,829,000. Nordea Investment Management AB increased its holdings in shares of Sarepta Therapeutics by 19.1% in the fourth quarter. Nordea Investment Management AB now owns 67,546 shares of the biotechnology company's stock worth $8,228,000 after acquiring an additional 10,815 shares in the last quarter. Allspring Global Investments Holdings LLC raised its holdings in Sarepta Therapeutics by 16,717.7% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 85,434 shares of the biotechnology company's stock worth $10,602,000 after buying an additional 84,926 shares during the period. Finally, Van ECK Associates Corp lifted its position in Sarepta Therapeutics by 24.4% in the 4th quarter. Van ECK Associates Corp now owns 84,834 shares of the biotechnology company's stock valued at $10,315,000 after acquiring an additional 16,658 shares in the last quarter. Institutional investors and hedge funds own 86.68% of the company's stock.

Insider Activity

In related news, Director Claude Nicaise sold 2,491 shares of Sarepta Therapeutics stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total transaction of $248,203.24. Following the transaction, the director now directly owns 27,812 shares of the company's stock, valued at $2,771,187.68. This trade represents a 8.22% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders own 7.70% of the company's stock.

Sarepta Therapeutics Stock Performance

SRPT stock traded up $0.07 during trading on Wednesday, reaching $36.27. The stock had a trading volume of 2,706,363 shares, compared to its average volume of 1,673,151. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The firm has a market cap of $3.56 billion, a PE ratio of 29.02 and a beta of 0.85. The stock's 50 day moving average is $64.03 and its two-hundred day moving average is $99.33. Sarepta Therapeutics, Inc. has a 52 week low of $34.90 and a 52 week high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share for the quarter, missing analysts' consensus estimates of $2.20 by ($5.62). The firm had revenue of $744.86 million for the quarter, compared to analysts' expectations of $685.75 million. Sarepta Therapeutics had a net margin of 7.43% and a return on equity of 11.00%. The firm's quarterly revenue was up 80.2% compared to the same quarter last year. During the same quarter last year, the firm posted $0.73 EPS. As a group, equities analysts anticipate that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. Piper Sandler dropped their target price on Sarepta Therapeutics from $110.00 to $70.00 and set an "overweight" rating on the stock in a report on Wednesday, May 7th. The Goldman Sachs Group cut their price objective on Sarepta Therapeutics from $178.00 to $100.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Evercore ISI downgraded Sarepta Therapeutics from an "outperform" rating to an "inline" rating and set a $50.00 price objective for the company. in a report on Thursday, May 8th. Morgan Stanley decreased their price objective on shares of Sarepta Therapeutics from $182.00 to $113.00 and set an "overweight" rating for the company in a research report on Wednesday, May 7th. Finally, Guggenheim decreased their price objective on shares of Sarepta Therapeutics from $112.00 to $98.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Six equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Sarepta Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $131.22.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.